Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Deals

Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies

Fineline Cube Nov 11, 2022

Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...

Company Drug

CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study

Fineline Cube Nov 11, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...

Company Drug

BeiGene’s Brukinsa Receives Marketing Approval in Brazil

Fineline Cube Nov 11, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...

Company Drug

Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs

Fineline Cube Nov 11, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...

Company Drug

Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study

Fineline Cube Nov 11, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...

Company Drug

3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...

Company Deals

Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab

Fineline Cube Nov 10, 2022

Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...

Company Drug

LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China

Fineline Cube Nov 10, 2022

Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...

Company Deals

Innovex Medical Files for IPO in Hong Kong to Boost Product Development

Fineline Cube Nov 10, 2022

Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed...

Company Drug

NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma

Fineline Cube Nov 10, 2022

The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug,...

Company Drug

Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918

Fineline Cube Nov 10, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...

Policy / Regulatory

China Releases 14th Five-Year Plan for National Health Informatization

Fineline Cube Nov 10, 2022

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and the National Bureau...

Company

Zai Lab Reports 33% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings...

Company Deals

GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline...

Company Drug

3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Boston Scientific Partners with Omron for Atrial Fibrillation Management

Fineline Cube Nov 10, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at...

Company Deals

Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study

Fineline Cube Nov 10, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...

Company

BeiGene Reports 88% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings...

Company Deals

Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE

Fineline Cube Nov 9, 2022

A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...

Posts pagination

1 … 593 594 595 … 657

Recent updates

  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
  • Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology
  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.